Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Chemomab Therapeutics Ltd CMMB

Healthcare Biotechnology
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing... see more

Current News (NDAQ:CMMB)

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

GlobeNewswire December 2, 2025

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

GlobeNewswire November 24, 2025

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 20, 2025

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

GlobeNewswire November 6, 2025

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 21, 2025

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2025

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

GlobeNewswire June 30, 2025

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

GlobeNewswire June 11, 2025

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

GlobeNewswire June 3, 2025
View More News ››

Opinion & Analysis (NDAQ:CMMB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CMMB)

Be the first to post on this bullboard.

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts